Today: 20 May 2026
AppLovin (APP) stock rises as Piper Sandler sticks with $800 target and BofA keeps $860 view
7 January 2026
2 mins read

AppLovin (APP) stock rises as Piper Sandler sticks with $800 target and BofA keeps $860 view

New York, January 7, 2026, 11:36 EST — Regular session

  • AppLovin shares rose about 2% in mid-morning trading, outperforming a flat broader market.
  • Piper Sandler reiterated an Overweight rating and $800 target; Benchmark kept a Buy with a $775 target.
  • Traders are watching for updates on holiday e-commerce ad performance ahead of an expected mid-February results report.

AppLovin (APP.O) shares rose about 2% on Wednesday, building on a choppy start to the year as fresh analyst notes kept attention on the company’s push into e-commerce advertising. The stock was up at $629.57, while the S&P 500 was little changed and the Nasdaq-100 ETF edged higher; rival Trade Desk fell.

The move matters because AppLovin’s next leg is still being priced in. Bulls are betting the company can broaden beyond mobile-game ads into web and e-commerce budgets, and the next earnings call is expected to put real numbers around that shift.

Piper Sandler reiterated its Overweight rating — meaning it expects the stock to outperform — and kept an $800 price target, pointing to signs of continued adoption through the fourth quarter and stronger checks around Black Friday/Cyber Monday. The firm also flagged ad-library work that it said showed paid marketing tests across more than 180 brands, including Apple and Amazon.

Benchmark, which named AppLovin a “2026” top idea, reiterated a Buy rating and a $775 target, arguing the story rests on two engines: the core gaming ad business and a growing web and e-commerce offering. It highlighted uptake in the self-serve Axon Ads Manager and improving “return on ad spend” — a measure of revenue generated per dollar of advertising — particularly in prospecting campaigns aimed at finding new customers. Investing.com

Bank of America Securities analyst Omar Dessouky also kept a Buy rating and an $860 target, citing growth in AppLovin’s Axon footprint inside online retail. He pointed to the company’s tracking pixel — a snippet of code used to measure ad performance — being installed across nearly 4,000 online merchants, and said fourth-quarter guidance could prove conservative if holiday spending trends hold up.

The core question for traders is whether those early signals show up in reported e-commerce revenue and retention, not just in anecdotal “checks.” Self-serve tools matter here because they can widen the advertiser base without leaning on large agency relationships, and investors are sensitive to any hint that the ramp is slowing.

But AppLovin’s e-commerce pitch sits on data, measurement and a steady flow of ad dollars — areas that can draw scrutiny and swing with the economy. The company has also faced questions about data-collection practices; the U.S. Securities and Exchange Commission has been probing the issue, Bloomberg reported in October, citing people familiar with the matter.

Next up, investors are circling the next earnings report, which TipRanks lists for Feb. 18 after the close, along with a consensus EPS forecast of $2.95 for the quarter. Management’s read on holiday e-commerce ad performance — and what that means for early 2026 spend — is likely to set the tone.

Stock Market Today

  • Euronext Q1 2026 Sees Record Trading Volumes and 15.3% Revenue Growth
    May 20, 2026, 5:43 AM EDT. Euronext reported a record Q1 2026 with cash equity trading and clearing revenue up 30.8% to €123 million, driven by high market volatility and the full contribution from Euronext Athens. Total underlying revenue rose 15.3% to €528.5 million, marking the exchange's eighth consecutive quarter of double-digit growth. Average daily cash equity transaction value in April reached €16.4 billion, with a 64.1% market share. Commodities trading revenue climbed 13.9%, while FX revenue grew 5.8%. ETF trading surged 84% since September 2025, boosted by the launch of mini ETF options. Adjusted EBITDA rose 16.7% to €343.2 million, with net income up 17.7%. Euronext declared a €3.18 dividend per share, reflecting a 50% payout, payable in May.

Latest articles

Co-Diagnostics Stock Surges — Then $3 Million Financing Puts The Rally To The Test

Co-Diagnostics Stock Surges — Then $3 Million Financing Puts The Rally To The Test

20 May 2026
New York, May 20, 2026, 05:08 EDT Co-Diagnostics shares face an early test on Wednesday after the diagnostic-test developer announced a $3 million private placement hours after its stock closed up 43.8% at $1.97 on Tuesday. Extended-hours trading showed the shares down 13.3% at $1.71 before the regular Nasdaq session. The timing matters. Co-Diagnostics had rallied after saying it had completed a strategy to develop an assay, or diagnostic test, for the Bundibugyo virus behind a fast-moving Ebola outbreak in Democratic Republic of Congo and Uganda. The late financing then shifted attention to dilution and cash needs. The company said
Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

Micron Stock Just Dodged the Nasdaq Selloff. A Samsung Strike Could Be Its Next Jolt

20 May 2026
Micron Technology shares rose 2.5% Tuesday to $698.74, lifting its market value near $798 billion as the Nasdaq fell. Analysts cited tight memory supply and strong DRAM and NAND pricing. A planned strike by 48,000 Samsung workers Thursday could disrupt global memory supply, potentially raising prices. Micron recently sampled 256GB DDR5 server modules to partners.
Wall Street Puts $150 Target on Intel in AI Push

Wall Street Puts $150 Target on Intel in AI Push

20 May 2026
Intel shares rose 2.43% to $110.80 on Tuesday, ending a five-day losing streak. The stock rebounded as analysts raised price targets, citing demand for AI server CPUs. Intel traded between $102.40 and $113.07 during the session. The Nasdaq Composite fell 0.84%, with Nvidia and AMD also down.
UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Previous Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Johnson & Johnson stock rises on Ottava robot FDA filing as investors scan pipeline updates
Next Story

Johnson & Johnson stock rises on Ottava robot FDA filing as investors scan pipeline updates

Go toTop